Vistagen Therapeutics Inc. (NASDAQ:VTGN) saw an upside of 7.83% to $6.20 after adding $0.45on Wednesday. The 5-day average trading volume is 798,788 shares of the company’s common stock. It has gained $6.10 in the past week and touched a new high 2 times within the past 5 days. An average of 5,088,242 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,172,363.
VTGN’s 1-month performance is 262.57% or $4.17 on its low of $1.63 reached on 08/04/23. The company’s shares have touched a 52-week low of $1.62 and high of $24.71, with the stock’s rally to the 52-week high happening on 08/07/23. YTD, VTGN has achieved 100.65% or $2.94 and has reached a new high 13 times. However, the current price is down -74.91% from the 52-week high price.
Valuation Metrics
VTGN stock has a beta of 0.11. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 3.56.
Vistagen Therapeutics Inc.’s quick ratio for the period ended March 30 was 3.80, with the current ratio over the same period at 3.80. The firm’s gross profit as reported stood at $59.04 million against revenue of -$0.23 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -186.67% to -$6.9 million, while revenue of -$12.23 million was -77.25% off the previous quarter. Analysts expected VTGN to announce -$1.5 per share in earnings in its latest quarter, but it posted -$1.75, representing a -16.70% surprise. EBITDA for the quarter stood at more than -$6.97 million. VTGN stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 8.18 million, with total debt at $3.28 million. Shareholders hold equity totaling $9.36 million.
Let’s look briefly at Vistagen Therapeutics Inc. (VTGN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 55.77% to suggest the stock is trending Neutral, with historical volatility in this time period at 124.24%.
The stock’s 5-day moving average is $5.63, reflecting a +6.63% or $0.38 change from its current price. VTGN is currently trading +250.87% above its 20-day SMA, +42.87% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +148.35% and SMA200 by+55.58%.
Stochastic %K and %D was 17.67% and 17.05% and the average true range (ATR) pointed at 1.40. The RSI (14) points at 56.63%, while the 14-day stochastic is at 19.09% with the period’s ATR at 1.38. The stock’s 9-day MACD Oscillator is pointing at -0.23 and -0.73 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Vistagen Therapeutics Inc. (NASDAQ: VTGN), Maxim Group upgraded it to a Buy rating. They previously had a Hold rating on the stock. Analysts offering their rating for VTGN stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate VTGN as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is VTGN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $30.00 and a high of $30.00, with their median price target at $30.00. Looking at these predictions, the average price target given by analysts is for Vistagen Therapeutics Inc. (VTGN) stock is $30.00.
